IC351 (tadalafil, Cialis): update on clinical experience.
about
Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's diseaseCurrent use of phosphodiesterase inhibitors in urologyPotency, selectivity, and consequences of nonselectivity of PDE inhibitionMirodenafil for the treatment of erectile dysfunction: a systematic review of the literature.New achievements and pharmacotherapeutic approaches to impotence in the elderly.Update on oral treatments for male erectile dysfunction.PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporterThe therapeutic dilemma: how to use tadalafil.Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem.Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Androgens, health and sexuality in women and men.Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta.Evaluation of sexual activity in patients treated with tadalafil: a randomized prospective placebo-controlled trial.Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.Phosphodiesterase Inhibitors Sildenafil and Vardenafil Reduce Zebrafish Rod Photoreceptor Outer Segment Shedding.Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation
P2860
Q24615907-A4403571-65A4-4DFE-8CA3-DDAE8C7F15C3Q26795512-6C2A82AC-C140-4B41-A5C6-E61AD37A3783Q28269129-11936F10-DF20-4BF4-89E7-86CD93306128Q33632138-A182BC4D-F90A-408E-AEA9-1C774C6D21CDQ35569842-4999F2B3-9329-4058-9F40-9C0C1B4028D9Q35750719-410BAD06-998E-4B69-BC4B-DCBAD80ECB24Q36124056-A0F6AD67-46C3-44D8-AE7F-A9DF01D48AD1Q36291011-EB9BDCFB-907E-440B-B257-AFA0BC39C87CQ36359845-BC763D85-0C36-4CE1-9139-762CFF6C9680Q36395193-40A4E983-CAC5-461D-A951-2B52E29009B5Q36543120-44C6A9A9-9685-4133-AA6A-3AB2CBD004B3Q36689825-25F48675-6792-4F9C-9ACA-A73F4606FAC1Q37813672-DFEE3E41-C00F-4634-A754-015FDBF38A46Q38047228-46CB139A-655A-480F-AE11-B69C6EE56D7FQ38815890-8D6F1E33-7AEC-45A8-95ED-18D1F2ED9B58Q44327827-22ED009E-008B-4799-BB39-C8A7E9F4EA13Q45128188-104139C2-B57B-454C-9C96-7B00A712EDAFQ45147066-FAACC26D-E202-4812-82DA-B6F0A47707B9Q46346834-124196E8-BFB6-4305-BE17-C89F63D93A55Q56781955-402D6A14-284C-4088-9536-414E701C53E7
P2860
IC351 (tadalafil, Cialis): update on clinical experience.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
IC351 (tadalafil, Cialis): update on clinical experience.
@ast
IC351 (tadalafil, Cialis): update on clinical experience.
@en
IC351 (tadalafil, Cialis): update on clinical experience.
@nl
type
label
IC351 (tadalafil, Cialis): update on clinical experience.
@ast
IC351 (tadalafil, Cialis): update on clinical experience.
@en
IC351 (tadalafil, Cialis): update on clinical experience.
@nl
prefLabel
IC351 (tadalafil, Cialis): update on clinical experience.
@ast
IC351 (tadalafil, Cialis): update on clinical experience.
@en
IC351 (tadalafil, Cialis): update on clinical experience.
@nl
P356
P1476
IC351 (tadalafil, Cialis): update on clinical experience.
@en
P2093
P2888
P304
P356
10.1038/SJ.IJIR.3900807
P478
14 Suppl 1
P577
2002-02-01T00:00:00Z
P5875
P6179
1040105814